Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (23036)	7/10/1998 9:58:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Mudcat, As others have noted, the mouse Neupogen market is rather small. I think that you are missing the point of the Science paper. This was a "proof of principle" paper. The first two authors are Ligand employees. SBH provided the library and LGND provided the screening technology. The screening technology can be applied to almost any polypeptide hormone. There are 100's of targets. SBH will develop the lead products, but LGND will file the patents and expand the technology to the new targets. Today's paper was a technology breakthrough, not a product breakthrough.